TY - JOUR T1 - Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply JO - RHEUMATOLOGY PY - 2008/10/01 AU - Wailoo A AU - Bansback N AU - Chilcott J ED - DO - DOI: 10.1093/rheumatology/ken326 VL - 47 IS - 10 SP - 1590 EP - 1590 Y2 - 2025/05/22 ER -